Search
Selected Filter
Filter Results
Displaying 1–10 of 389 diseases results
-
Mar 27, 2024
Nanoscope Plans to Apply for FDA Approval for its Optogenetic Therapy
The company reported positive two-year results for its Phase 2 clinical trial of MCO-010.
-
Mar 26, 2024
Opus Reports Vision Improvements for Patients in LCA5 Gene Therapy Clinical Trial
The company plans to administer a higher dose of the emerging gene therapy to the next group of patients.
-
Mar 25, 2024
Collaboration will add a new multi-gene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness.
-
Mar 25, 2024
Adopted into a musical family, Miles Hoyt picked up a guitar at just four years old, and he hasn’t stopped playing since. Now Miles, who has Stargardt disease, and his parents are using music to bring their community together to raise funds for blinding diseases with their Raising Our Sights fundraiser, Smiles for Miles.
-
Mar 11, 2024
Influencing Positivity for the Disabled Community
Content creator and social media influencer Stephanie Renberg uses her platforms to raise awareness for blindness and disabilities in hopes that her openness about her Stargardt disease will contribute to a more inclusive and understanding world.
-
Mar 8, 2024
Eye on the Cure Podcast | Episode 63: Dr. Hema Ramkumar
Hema Ramkumar, MD, a retinal specialist, surgeon, and founder of the company Oculogenex, talks with host Ben Shaberman about her emerging therapy that targets mitchondria to slow the progression of intermediate dry age-related macular degeneration and potentially other retinal diseases. She also discusses her experiment that will put mice in space so researchers can gain a better understanding of retinal degeneration.
-
Feb 23, 2024
Eye on the Cure Podcast | Episode 62: Dr. Peter Quinn
Peter Quinn, PhD, a principal investigator and associate research scientist at Columbia University, talks to host Ben Shaberman about the promise of emerging CRISPR/Cas9 gene editing therapies, including base and prime editing approaches, for inherited retinal diseases. Dr. Quinn also reviews gene editing projects ongoing in his lab for patients with mutations in CRB1 and PRPH2.
-
Feb 21, 2024
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
Known as retinal progenitors, the company’s jCells® are designed to preserve photoreceptors in people with retinitis pigmentosa (RP) and other retinal diseases.
-
Feb 9, 2024
The company plans to begin a Phase 2/3 clinical trial for the treatment during the first half of 2024.
-
Feb 6, 2024
Foundation Fighting Blindness Launches GYROS, a Natural History Study for People with Gyrate Atrophy
Gyrate atrophy is an inherited retinal disease—causing progressive vision loss. GYROS results will help researchers design clinical trials for an emerging gyrate atrophy gene therapy.